


CLAIMS

What is claimed is:

- 5 1. Use of a compound in the manufacture of a medicament for the treatment of inflammatory bowel disease, said compound comprising




or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof;

wherein

- 10 Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group; A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be substituted with S or O; or A is  $-(CH_2)_m-Ar-(CH_2)_o-$  wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one  $CH_2$  may be substituted with S or O; and
- 15 B is aryl or heteroaryl.

2. The use of claim 1, wherein Y is selected from the group consisting of  $CO_2(R^2)$ ,  $CON(R^2)_2$ ,  $CON(OR^2)R^2$ ,  $CON(CH_2CH_2OH)_2$ ,  $CONH(CH_2CH_2OH)$ ,  $CH_2OH$ ,  $P(O)(OH)_2$ ,  $CONHSO_2R^2$ ,  $SO_2N(R^2)_2$ ,  $SO_2NHR^2$ , and tetrazolyl- $R^2$ ; wherein  $R^2$  is independently H,  $C_1$ - $C_6$  alkyl, phenyl, or biphenyl.


3. The use of claim 1 or 2, said compound comprising



or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof;


wherein G is 1,3-interaryl or interheteroaryl, or  $-(CH_2)_3-$ .

4. The use of any one of claims 1 to 3 wherein B is phenyl.
5. The use of any one of claims 1 to 4 wherein B is alkylphenyl.
- 25 6. The use of claim 5 wherein B is *p-t*-butylphenyl.
7. The use of claim 4 wherein B is hydroxyalkylphenyl.
8. The use of claim 1, said compound comprising



or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof,  
wherein  $R^7$  is linear alkyl comprising 3, 4, 5, 6 or 7 carbon atoms.


9. The use of claim 1, said compound comprising



or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof;  
wherein a dashed line indicates the presence or absence of a bond;  
R is hydrocarbonyl or hydroxyhydrocarbonyl having from 1 to 12 carbon atoms;  
X is  $CH_2$ , O, or S; and

G is 1,3-interaryl or interheteroaryl, or  $-(CH_2)_3-$ .


10. The use of claim 9, said compound comprising



or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof,  
wherein  $X^1$  and  $X^2$  are independently CH, O, or S; and


$R^7$  is linear alkyl comprising from 3 to 7 carbon atoms.

11. The use of claim 1 or 2, said compound comprising



or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof.

12. The use of claim 11, said compound comprising



5 or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof,  
wherein X<sup>1</sup> and X<sup>2</sup> are independently CH, O, or S.

13. A compound selected from the group consisting of

5-[(R)-1-(4-*tert*-Butyl-phenyl)-5-oxo-pyrrolidin-2-ylmethoxy]-pentanoic acid;

3-[(R)-1-(4-*tert*-Butyl-phenyl)-5-oxo-pyrrolidin-2-ylmethoxymethyl]-benzoic acid;

10 5-[(R)-1-(4-*tert*-Butyl-phenyl)-5-oxo-pyrrolidin-2-ylmethoxymethyl]-furan-2-carboxylic acid;

5-[(R)-1-(4-*tert*-Butyl-phenyl)-5-oxo-pyrrolidin-2-ylmethoxymethyl]-thiophene-2-carboxylic acid;

7-[(S)-1-(4-*tert*-Butyl-phenyl)-5-oxo-pyrrolidin-2-yl]-heptanoic acid;

5-[(R)-1-[4-(1-Hydroxy-hexyl)-phenyl]-5-oxo-pyrrolidin-2-ylmethoxymethyl]-furan-2-carboxylic acid;

5-[(R)-1-[4-(1-Hydroxy-2-methyl-propyl)-phenyl]-5-oxo-pyrrolidin-2-ylmethoxymethyl]-furan-2-carboxylic acid;

15 5-[(R)-1-[4-(1-Hydroxy-2-phenyl-ethyl)-phenyl]-5-oxo-pyrrolidin-2-ylmethoxymethyl]-furan-2-carboxylic acid;  
and

5-[(R)-1-[4-(1-Hydroxy-hexyl)-phenyl]-5-oxo-pyrrolidin-2-ylmethoxymethyl]-thiophene-2-carboxylic acid.

14. A composition comprising a compound according to claim 13, wherein said composition is a liquid which is ophthalmically acceptable.

20 15. Use of a compound according to claim 13 in the manufacture of a medicament for the treatment of glaucoma or ocular hypertension.